<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839354</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002344</org_study_id>
    <secondary_id>PECARN Protocol Number 050</secondary_id>
    <secondary_id>UG3HL148560</secondary_id>
    <nct_id>NCT04839354</nct_id>
  </id_info>
  <brief_title>Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial</brief_title>
  <acronym>STArT</acronym>
  <official_title>Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial of IV arginine therapy in children with Vaso-occlusive painful episodes (VOE) in&#xD;
      sickle cell disease (SCD) is designed to further knowledge on efficacy and safety of the&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is designed as a double-blind, placebo controlled, randomized, phase 3,&#xD;
      multi-center trial of IV arginine therapy in children with Vaso-occlusive painful episodes&#xD;
      (VOE) in sickle cell disease (SCD) to further knowledge on efficacy and safety of the&#xD;
      therapy. The exploratory objective is to more fully characterize the arginine metabolome in&#xD;
      children with SCD during VOE, and evaluate the effects of arginine therapy on global arginine&#xD;
      bioavailability and mitochondrial function together with important clinical outcomes (time to&#xD;
      VOE resolution, pain scores, total parenteral opioid use, Patient-Reported Outcomes (PROs),&#xD;
      and hospital length of stay in children with SCD and VOE.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">April 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in time-to-crisis resolution</measure>
    <time_frame>Date and time of first study drug administration and last IV opioid treatment - up to 2 months</time_frame>
    <description>Time in hours from study drug delivery to time of last dose of parenteral opioid delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total parenteral opioid use</measure>
    <time_frame>Time of IV placement, opioid monitoring up to 2 months</time_frame>
    <description>Total parenteral opioid use (morphine equivalents, mg/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain scores</measure>
    <time_frame>Time of IV placement, and on the day of discharge up to 2 months</time_frame>
    <description>Daily highest and lowest pain scores will be recorded. 0-10 scale, 10 is strongest pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Pain Interference score</measure>
    <time_frame>Within 12 hours of study drug delivery, and on the day of discharge up to 2 months</time_frame>
    <description>PROMIS: pain Interference (8 items). PROMIS measures are scored on the T-score metric. High scores mean more of the concept being measured (e.g., more pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Pain Behavior score</measure>
    <time_frame>Within 12 hours of study drug delivery, and on the day of discharge up to 2 months</time_frame>
    <description>PROMIS: pain behavior (8 items). PROMIS measures are scored on the T-score metric. High scores mean more of the concept being measured (e.g., more pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS Fatigue score</measure>
    <time_frame>Within 12 hours of study drug delivery, and on the day of discharge up to 2 months</time_frame>
    <description>PROMIS: fatigue (8 items). PROMIS measures are scored on the T-score metric. High scores mean more of the concept being measured (e.g., more fatigue).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Medication Quantification Score (MQS)</measure>
    <time_frame>Pre-dose and on day of discharge up to 2 months</time_frame>
    <description>Medication Quantification Score (MQS) is a tool to objectively quantify pain. It computes a single numeric value for a patient's pain medication profile. This number is used to track pain levels through a treatment course.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital length of stay in children</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Hospital length of stay in children (days) will be recorded.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Pediatric PROMIS score</measure>
    <time_frame>Within 12 hours of study drug delivery, and on the day of discharge up to 2 months</time_frame>
    <description>Pediatric PROMIS: (35 items) To be completed by patients ages 8-17 years of age and parents of children ages 5-17 years of age: (a)pain behavior (8 items), (b)pain interference (8 items), (c)pain intensity (1 item), (d)physical stress experiences (8 items), (e)fatigue (10 items). PROMIS measures are scored on the T-score metric. High scores mean more of the concept being measured (e.g., more fatigue).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Pediatric QL SCD score</measure>
    <time_frame>Within 12 hours of study drug delivery, and on the day of discharge up to 2 months</time_frame>
    <description>Peds QL SCD module (19 items) to be completed by children ages 5-17 years of age and parents of children ages 3-17 years of age: (a)Pain and Hurt (9 items), (b)Pain Impact (10 items)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Arginine bioavailability</measure>
    <time_frame>Prior to study drug delivery (pre-Dose), on day 2 and prior to discharge up to 2 months</time_frame>
    <description>Pharmacokinetic study will measure peak plasma arginine concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in mitochondrial function</measure>
    <time_frame>Prior to study drug delivery (pre-Dose), on day 2 and prior to discharge up to 2 months</time_frame>
    <description>Mitochondrial respiratory complex activities will be measured to estimate mitochondrial function</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Arginine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arginine is a nutritional supplement in parenteral form</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginine Hydrochloride</intervention_name>
    <description>One-time L-arginine loading dose (200 mg/kg IV) + standard dose (100 mg/kg IV TID)</description>
    <arm_group_label>Arginine Hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Placebo (normal saline) loading dose (2ml/kg IV) + 1ml/kg IV TID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 3-21 years of age, inclusive; AND&#xD;
&#xD;
          2. Established diagnosis of sickle cell disease (any genotype); AND&#xD;
&#xD;
          3. Pain requiring medical care in an acute care setting (ED, hospital ward, day hospital,&#xD;
             clinic) not attributable to non-sickle cell causes, treated with parenteral opioids.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Responds to 2 doses of IV opioids sufficiently for outpatient management&#xD;
&#xD;
          2. Greater than 12 hours from first dose of intravenous opioids to treat current pain in&#xD;
             acute care setting&#xD;
&#xD;
          3. Hemoglobin less than 5 gm/dL or emergent need for red blood cell transfusion for&#xD;
             hemodynamically unstable patient; OR&#xD;
&#xD;
          4. Ketamine use in the emergency department for treatment of VOE; OR&#xD;
&#xD;
          5. Glutamine within 30 days; OR&#xD;
&#xD;
          6. New SCD drug use &lt; 3 months (e.g. Hydroxyurea, voxelotor, crizanlizumab, etc) OR&#xD;
&#xD;
          7. Acute mental status or neurological changes; OR&#xD;
&#xD;
          8. Acute stroke or clinical concern for stroke; OR&#xD;
&#xD;
          9. Three or more ED visits for sickle cell related pain receiving parenteral opioids in&#xD;
             previous 7 days (not including current ED visit); OR&#xD;
&#xD;
         10. Hospital discharge within previous 7 days; OR&#xD;
&#xD;
         11. Hypotension requiring clinical intervention; hemodynamic instability; septic shock; OR&#xD;
&#xD;
         12. Previous randomization in this arginine phase 3 RCT; OR&#xD;
&#xD;
         13. Use of inhaled nitric oxide, sildenafil or arginine within the last month; OR&#xD;
&#xD;
         14. Non-English or non-Spanish speaking; OR&#xD;
&#xD;
         15. pregnancy; OR&#xD;
&#xD;
         16. Allergy to arginine; OR&#xD;
&#xD;
         17. PI/clinical team concerns for compliance/issues that may adversely impact study&#xD;
             participation/outcome; OR&#xD;
&#xD;
         18. Adults 18 years or older who lack medical decision-making capacity to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Morris, MD</last_name>
    <phone>404-785-7141</phone>
    <email>claudia.r.morris@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Hughes Spalding</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>03322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Morris, MD</last_name>
      <phone>404-785-7141</phone>
      <email>claudia.r.morris@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University/St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital/Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin/Wisconsin Children's Hospital</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Claudia R. Morris MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Arginine Therapy</keyword>
  <keyword>Pain management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Will be available starting 2029</ipd_time_frame>
    <ipd_access_criteria>No restrictions</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

